Osteoclast Inhibition and Bone Formation
Completed · Early Phase 1 · Has a placebo group
Conditions studied: Bone Loss, Aging
In brief
This protocol addresses: 1) How gene expression changes in bone cells are affected by aging? 2) Is aging associated with decreased signaling between bone cells? 3) How does treatment with the osteoporosis medication denosumab affect bone cell signaling?
Key facts
- Study ID
- NCT02554695
- Run by
- Mayo Clinic
- People needed
- 81
- Starts
- 2015-10-20
- Expected to finish
- 2016-10-25
- Last updated by the study team
- 2018-01-05
Who can join
Age: 25 and older, up to 80. Sex: female. Healthy volunteers: accepted.
Where it is running
- Mayo Clinic in Rochester — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.